On July 30, 2021, Rachel K. King, President of the Company, notified the Board of Directors of GlycoMimetics, Inc. of her decision to retire from those positions, effective as of August 6, 2021. Mrs. King will remain as an employee of the Company until August 31, 2021. On August 2, 2021, the Board appointed Harout Semerjian as the Company’s President, effective as of August 6, 2021. In connection with Mr. Semerjian’s appointment as President, on August 2, 2021 the Board also expanded the authorized size of the Board from seven to eight members and appointed Mr. Semerjian to fill the newly created vacancy, to be effective concurrently with the effectiveness of his appointment as President and Chief Executive Officer. Mr. Semerjian will serve in the class of directors whose term will expire at the Company 2022 Annual Meeting of Stockholders. The Company does not expect that Mr. Semerjian will be named as a member of any committees of the Board.
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers. It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4).